Inhibitor of Nuclear Factor Kappa B Kinase Subunit
Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or
IKBKB or EC 2.7.11.10)- Inhibitor
of nuclear factor kappa-B kinase subunit beta is a protein encoded by
the IKBKB gene. It plays an essential role in the NF-kappa-B signaling pathway
which is activated by multiple stimuli such as inflammatory cytokines,
bacterial or viral products, DNA damages or other cellular stresses. It acts as
part of the canonical IKK complex in the conventional pathway of NF-kappa-B
activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine
residues. Free NF-kappa-B is translocated into the nucleus and activates the
transcription of hundreds of genes involved in immune response, growth control,
or protection against apoptosis.
Inhibitor of Nuclear Factor Kappa B Kinase Subunit
Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or
IKBKB or EC 2.7.11.10) pipeline Target constitutes close to 8 molecules. Out of
which approximately 6 molecules are developed by companies and remaining by the
universities/institutes. The molecules developed by companies in Preclinical
stages are 6 respectively. Similarly, the universities portfolio in Preclinical
and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology,
Immunology and Gastrointestinal which include indications Glioblastoma
Multiforme (GBM), Inflammation, Acute Myelocytic Leukemia (AML, Acute
Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Inflammatory Bowel
Disease, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate
Cancer, Rheumatoid Arthritis, Solid Tumor and Squamous Cell Carcinoma.
The latest report Inhibitor of Nuclear Factor Kappa
B Kinase Subunit Beta-Pipeline Review, H1 2018, outlays comprehensive
information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta
(Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB
or EC 2.7.11.10) targeted therapeutics, complete with analysis by indications,
stage of development, mechanism of action (MoA), route of administration (RoA)
and molecule type. It also reviews key players involved in Inhibitor of Nuclear
Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase
Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics
development with respective active and dormant or discontinued projects.
The report is built using data and information
sourced from proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party
sources.
The report provides a snapshot of the global
therapeutic landscape for Inhibitor of Nuclear Factor Kappa B Kinase Subunit
Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or
IKBKB or EC 2.7.11.10)
The report reviews Inhibitor of Nuclear Factor Kappa
B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I
Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
The report features descriptive drug profiles for
the pipeline products which includes, product description, descriptive MoA,
R&D brief, licensing and collaboration details & other developmental
activities
The report reviews key players involved in Inhibitor
of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B
Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted
therapeutics and enlists all their major and minor projects
The report assesses Inhibitor of Nuclear Factor
Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or
I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics based on
mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and
discontinued pipeline projects
The report reviews latest news and deals related to
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF
Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
targeted therapeutics
Reasons to buy
Gain strategically significant competitor
information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong
product portfolio and create effective counter-strategies to gain competitive
advantage
Identify and understand the targeted therapy areas
and indications for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta
(Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB
or EC 2.7.11.10)
Identify the use of drugs for target identification
and drug repurposing
Identify potential new clients or partners in the
target demographic
Develop strategic initiatives by understanding the
focus areas of leading companies
Plan mergers and acquisitions effectively by
identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by
understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear
Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC
2.7.11.10) development landscape
Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
Key Topics covered in the report:-
Inhibitor Nuclear Factor
Inhibitor Nuclear Factor Market Growth
Kappa B Inhibitor Kinase Beta
Kappa B Inhibitor Kinase Beta Market growth
Inhibitor Nuclear Factor Market Analysis
Inhibitor Nuclear Factor Market Trends
Inhibitor Nuclear Factor Market Strategy
Kappa B Inhibitor Kinase Beta Market Analysis
Market Report Kappa Kinase Subunit Beta
Kappa B Inhibitor Kinase Beta Market Strategy
Products under Investigation by Universities
For more information on the research report, refer to below
link:
Related Reports:-
Contact :
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
+91-9015378249
